Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead candidate, TSHA-102, is an intrathecally delivered AAV9 gene therapy designed to deliver functional MECP2 to CNS cells and is in… From the company’s description.
Over the twelve months to Jun 30, 2026, Taysha Gene Therapies, Inc. reported revenue of $5.49M, down 32.3% from a year earlier, and a net loss of $149.63M. Operations used $132.19M in cash. In fiscal 2025, it reported revenue of $9.77M, up 17.3% from fiscal 2024, and a net loss of $109.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Taysha Gene Therapies, Inc. does
In the company’s own words
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead candidate, TSHA-102, is an intrathecally delivered AAV9 gene therapy designed to deliver functional MECP2 to CNS cells and is in clinical development for Rett syndrome, primarily in females. The REVEAL program includes Phase 1/2 trials and a pivotal study in patients aged 6 to under 22, while the ASPIRE study evaluates younger children. Taysha also has earlier-stage programs including TSHA-113, an AAV9 therapy targeting tau for tauopathies, and TSHA-114 for Fragile X syndrome; it discontinued development of TSHA-106 for Angelman syndrome in 2025. The company focuses on discovering, developing and potentially commercializing gene therapies for CNS disorders, including rare and larger patient populations. Its programs include one-time treatment approaches, with TSHA-102 delivered by lumbar intrathecal administration. Taysha regained full global rights to TSHA-102 in 2025 after an option agreement expired without exercise.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DALLAS, TX
- Fiscal year end
- December
- CIK
- 1806310
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Taysha Gene Therapies, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Taysha Gene Therapies, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Taysha Gene Therapies, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Taysha Gene Therapies, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Taysha Gene Therapies, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Taysha Gene Therapies, Inc.'s last four quarterly filings that the numbers alone won't show?”